Department of Cardiology, Ochsner Medical Center, Ochsner Clinical School, University of Queensland, New Orleans, Louisiana, USA.
Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
J Am Coll Cardiol. 2022 Jul 12;80(2):155-170. doi: 10.1016/j.jacc.2022.05.007.
Significant advances in the field of carotid artery stenting (CAS) have occurred, including new randomized trial data, recent professional societal statements for competency, new techniques and new devices that have been developed, and perhaps most importantly, our understanding of how to better select candidates for CAS to avoid periprocedural complications. The current Centers for Medicare and Medicaid Services coverage decision regarding CAS is outdated, and our review supports our recommendation to approve CAS in selected candidates who are symptomatic with a carotid stenosis ≥50% and ≤99% and for asymptomatic patients with carotid stenosis ≥70% and ≤99% for stroke prevention. Optimized CAS strategies have allowed experienced operators to better assess procedure risk before CAS and have led to continued improvement in CAS outcomes. New technologies including enhanced embolic protection devices and dual-layered stents should result in further improvement.
在颈动脉支架置入术 (CAS) 领域取得了重大进展,包括新的随机试验数据、最近针对能力的专业社会声明、新的技术和新的设备的开发,也许最重要的是,我们对如何更好地选择 CAS 候选者以避免围手术期并发症的理解。目前,医疗保险和医疗补助服务中心 (Centers for Medicare and Medicaid Services) 关于 CAS 的覆盖范围决定已经过时,我们的审查支持我们的建议,即在有症状的颈动脉狭窄≥50% 且≤99%的患者和无症状的颈动脉狭窄≥70% 且≤99%的患者中,批准选择性 CAS 用于预防中风。优化的 CAS 策略使有经验的操作者能够在 CAS 前更好地评估手术风险,并导致 CAS 结果的持续改善。包括增强型栓塞保护装置和双层支架在内的新技术应会带来进一步的改善。